Landmark pathogenesis

Opelz G, Henderson R.

Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients.
Lancet Dec 18-25, 1993; 342:1514-16.
Description: Study documents incidence of PTLD and association between aggressiveness and degree of immunosuppressive regimen.
PubMed citation number: 7902900.

Weissmann DJ, Ferry JA, Harris NL, Louis DN, Delmonico F, Spiro I.

Posttransplant lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin.
Am J Clin Path. June 1995; 103:748-55. .
Description: Study identifies origin of majority of cases of PTLD is host rather than donor.
PubMed citation number: 7785662

Liebowitz D.

Epstein-Barr virus and a cellular signaling pathway in lymphomas from mmunosuppressed patients.
NEJM May 14, 1998; 338:1413-21. .
Description: Demonstrates signaling pathways involved in pathogenesis of EBV-positive lymphomas.
PubMed citation number: 9580648

Landmark clinical diagnosis/prognosis

Walker RC, Marshall WG, Strickler JG, Wiesner RH, Velosa JA, Habermann TM, McGregor CG, Paya CV.

Pretransplantation assessment of the risk of lymphoproliferative disorder.
Clin Infect Dis May 1995; 20:1346-53.
Description: Report of the pretransplant factors that increase the risk for an individual to develop PTLD.
PubMed citation number: : 7620022.

Leblond V, Dhedin N, Mamzer Bruneel MF, Choquet S, Hermine O, Porcher R, Nguyen Quoc S, Davi F, Charlotte F, Dorent R, Barrou B, Vernant JP, Raphael M, Levy V.

Identification of prognostic factors in 61 patients with posttransplantation
lymphoproliferative disorders.
JCO Feb 1, 2001; 19:772-8.
Description: Report of the prognostic factors and long-term outcomes in patients with PTLD.
PubMed citation number: 11157030.

Landmark treatment

Nalesnik MA, Jaffe R, Starzl TE, Demetris AJ, Porter K, BurnhamJA, Makowka L, Ho M, Locker J.

The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression.
Am J Pathol Oct 1988; 133:173-92.
Description: Establishes reduction of immunosuppressive regimen as first line treatment approach for patients with PTLD.

Swinnen LJ, Mullen GM, Carr TJ, Costanzo MR, Fisher RI.

Aggressive treatment for postcardiac transplant lymphoproliferation.
Blood Nov 1, 1995; 86:3333-40.
Description: Demonstrates feasibility of aggressive chemotherapy in patients with PTLD that fails to respond to reduction of immunosuppressive regimen.
PubMed citation number: 7579436.

Milpied N, Vasseur B, Parquet N, Garnier JL, Antoine C, Quartier P, Carret AS, Bouscary D, Faye A, Bourbigot B, Reguerre Y, Stoppa AM, Bourquard P, Hurault de Ligny B, Dubief F, Mathieu-Boue A, Leblond V.

Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients.
Ann Oncol 2000; 11 suppl 1:113-6.
Description: Report on efficacy of monoclonal antibody based therapy for treatment of PTLD.
PubMed citation number: 10707791.

Review articles

Paya CV, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G, Habermann TM, Wiesner PH, Swinnen JL, Woodle ES, Bromberg JS.

Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. A ASTS/ASTP EBV-PTLD Task Force and the Mayo Clinic Organized International Consensus Development Meeting.
Transplantation November 27, 199; 68:1517-25.
PubMed citation number: 10589949.

Return to Table of Contents